|
|
|
|
|
18.02.26 - 14:33
|
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology (Business Wire)
|
|
|
New financing program provides a “one-stop” pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives
Supports improved conversion of late-stage prospects as reimbursement clarity accelerates purchase decisions and lowers breakeven point to only one patient per monthBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structures.
Sensus Healthcare Financial Services is intended to support the acquisition of Sensus' full line of SRT and IG-SRT systems through customer-friendly financing structures and terms. The Company ...
|
|
|
|
|
|
|
|
|
12.02.26 - 22:09
|
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer (Business Wire)
|
|
|
2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026
Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability
Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer
Conference call begins at 4:30 p.m. Eastern time todayBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025.
Highlights include the following:
Revenues were $4.9 million for the quarter and $27.5 million for the year
Net loss was $3.2 million for the quarter and $7.7 million ...
|
|
|
05.02.26 - 14:03
|
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026 (Business Wire)
|
|
|
BOCA RATON, Fla.--(BUSINESS WIRE)--$SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and...
|
|
|
07.01.26 - 14:36
|
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors (Business Wire)
|
|
|
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors.
Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologies. He currently serves as President, Imaging for the U.S. and Canada at GE HealthCare, where he is responsible for the company's largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Me...
|
|
|
|
|
|
|
|
|
|
|
14.11.25 - 14:03
|
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer (Business Wire)
|
|
|
New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT® codes for office-based SRT and the growing commercial opportunity the Company now facesBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel® software and related service models.
These expanded responsibilities follow a recent reimbursement milestone from the Centers for Medicare & Medicaid Services (CMS), which established current procedural terminology (CPT) codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-m...
|
|
|
|
|
|
|
12.11.25 - 14:06
|
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors (Business Wire)
|
|
|
Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellenceBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall.
Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operational improvement. He currently serves as Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm based in Lynnfield, Mass., where he leads firmwide advisory strategy, operational oversight, financial planning innovation and multi-disciplinary client service execution. Sinc...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
